FDA finalizes new 510(k) guidance for dental composite resins and dental curing lights

On 2 September 2026, the U.S. Food and Drug Administration (FDA) issued two final, Level 1 guidances addressing the content of premarket notification submissions for dental composite resin devices and dental curing lights. The Agency announced both guidances in a single Federal Register notice, 91 FR 56452 to 56454. They replace the corresponding legacy guidances from 2005 and 2006 and crystallize FDA’s current expectations for device characterization, predicate comparison, non-clinical evidence, labeling, and, in the case of curing lights, software, cybersecurity, electrical safety, electromagnetic compatibility, and wireless technology.

The practical significance is considerable. For composite resins, the final guidance moves the submission dossier toward a more explicit formulation-driven and risk-informed evidence package. It expects complete quantitative chemistry, including a 100-percent-by-mass accounting of each formulation; release characterization for fluoride and other eluting constituents; targeted physical, mechanical, and curing-performance data; and a shelf-life strategy that couples accelerated aging with parallel real-time confirmation. For curing lights, the guidance recognizes the device as a potentially complex electromechanical and software-enabled system, requiring evidence on radiant output, spectral characteristics, distance attenuation, beam uniformity, thermal safety, reprocessing, software, connectivity, and where applicable, cybersecurity.

Legal and regulatory context

The FDA issued the two documents through the Center for Devices and Radiological Health (CDRH) and announced their availability on the same date in the Federal Register. The notice explains that the guidances provide recommendations for device description, performance testing, and labeling in 510(k) submissions, and that they are intended to promote consistency and facilitate efficient review. FDA also confirms that it considered comments submitted on the July 2024 draft guidances before finalization.

The documents have the legal character of FDA guidance. They describe the Agency’s current thinking; they do not independently create enforceable rights or obligations; and a manufacturer may use an alternative approach if it satisfies the applicable statutes and regulations. This qualification is not merely formal. It means that a submission team should distinguish carefully between: first, an explicit legal or regulatory requirement; second, an FDA recommendation in the guidance; and third, a sponsor-specific scientific rationale for a different method. Nevertheless, the guidance is the clearest available statement of the evidence and presentation that FDA reviewers are likely to expect for these device categories.

For both device types, the guidance supplements the general content requirements for a 510(k) submission, including the predicate comparison required under 21 CFR 807.87(f). Substantial equivalence therefore remains the analytical center of the premarket case. The new recommendations do not displace the need for a legally marketed predicate, a side-by-side comparison of relevant technological characteristics, or a defensible explanation of why any differences do not raise different questions of safety and effectiveness.

Scope: determine first whether the device is actually covered

A disciplined scope determination should be the opening step of any remediation exercise. The composite-resin guidance is limited to products regulated under 21 CFR 872.3690 and 21 CFR 872.3765, specifically product codes EBF (Tooth Shade Resin Material) and EBC (Pit and Fissure Sealant and Conditioner). It does not encompass resin restoratives intended for uses such as cementing, coating, fixation, or temporary restoration, although it applies to composite resins that are combination products without addressing combination-product-specific considerations.

The curing-lights guidance is limited to devices regulated under 21 CFR 872.6070, product code EBZ, including broad-beam and monochromatic light sources classified under that regulation. It does not cover laser devices for polymerization or devices intended exclusively for tooth whitening. This distinction matters because a product’s intended use, source technology, and labeling may move it outside the guidance’s scope even if it is marketed in a dental setting.

Dental composite resin devices: formulation transparency becomes a central submission discipline

The final composite-resin guidance recommends a complete description of each formulation, component, and accessory that will be marketed with the device. The proposed chemical composition should identify polymers, monomers, initiators, curing agents, stabilizers, plasticizers, eluting agents, fillers, colorants, and other additives. FDA recommends quantification by mass percentage, with each formulation totaling 100 percent by mass. Substances should be identified with a Chemical Abstracts Service (CAS) Registry Number where available; color additives may instead be identified through the relevant color-additive regulations or a Colour Index number where available.

This is more than a request for a generic bill of materials. It puts formulation control and formulation comparability at the center of the substantial-equivalence story. A submission should enable a reviewer to see precisely which chemical constituents are present in the subject device, where they occur, which components are patient-contacting, and how they compare with the predicate’s corresponding materials. In practice, that means avoiding aggregation that obscures relevant substances, especially where a formulation contains reactive monomers, polymerization initiators, colorants, plasticizers, or intentionally eluting ingredients.

Where the device contains fluoride or other eluting agents, the guidance recommends quantitative release profiles over time. FDA specifically describes a cumulative-release plot for ions released from a representative sample, measured in distilled water at 37 °C over seven days with daily water replacement. The Agency identifies calcium, phosphorus, and nitrate ions as examples of other eluents. A manufacturer should therefore connect the chemistry narrative, release test method, acceptance rationale, and labeling claim. If a product claims remineralization, anticaries activity, or other clinical benefit attributable to an eluting ingredient, the adequacy of this evidence package becomes particularly important.

Mechanical, physical, and curing-performance evidence

The final guidance identifies a structured non-clinical testing package for composite resins. It recommends testing under current FDA-recognized versions of relevant standards, including ISO 4049, ISO 6874, and ISO 9917-2 as applicable. The recommended attributes include flexural strength, water absorption, water solubility, compressive strength, elastic modulus, and surface hardness. The guidance also addresses filler-particle-size information where a manufacturer makes “hybrid” or “nanofilled” claims.

For photoinitiated resin systems, FDA recommends evidence on the energy needed to cure the material: light intensity or radiant exitance, wavelength, curing time for every shade, and depth of cure under the specified test condition. These data should not be treated as an isolated resin test package. They are the technical interface between the restorative material and the curing light. The chosen test approach should establish that the labeled curing parameters can reliably deliver a resin with the expected properties across intended shades, thicknesses, and operational modes.

Shelf life and biological evaluation: two areas where oversimplification creates avoidable risk

The composite-resin guidance recommends a shelf-life strategy that evaluates critical device properties throughout the proposed expiration period. It directs sponsors to repeat relevant mechanical and other aging-sensitive bench tests, to explain the aging conditions and rationale, and to use the currently FDA-recognized ASTM F1980 standard when accelerated aging is used. Because these devices consist of polymeric materials, FDA recommends testing real-time-aged samples to confirm accelerated-aging findings. That confirmation should occur in parallel with 510(k) review and clearance; its results are to be documented in the design-and-development files, although complete test reports need not be submitted to FDA.

This nuance deserves emphasis. The final guidance does not say that a full real-time aging data package must already be contained in every 510(k). It does, however, make clear that a sponsor should not regard an accelerated study as a self-sufficient endpoint for polymeric composite resins. The appropriate planning response is to begin real-time aging early, lock the protocols, place the relevant configurations and worst cases on stability, and ensure that the quality-system record can demonstrate continued confirmation after clearance.

For biocompatibility, FDA characterizes dental composite resins as external communicating devices with permanent contact with tissue, bone, or dentin. The guidance recommends a biological evaluation that considers cytotoxicity, sensitization, irritation or intracutaneous reactivity, acute systemic toxicity, subacute/subchronic toxicity, and genotoxicity, drawing on ISO 7405 and FDA’s approach to ISO 10993-1 as appropriate.

However, the guidance should not be read as imposing an automatic new-test requirement in every case. FDA permits reliance on prior testing experience, literature, recognized consensus standards, or a device master file where the material, manufacturing and processing method, nature of contact, and contact duration are sufficiently aligned with a legally marketed device with a safe-use history. The essential task is to construct a traceable risk-based rationale rather than to assume that “same material name” or a CE/MDR data package alone establishes biological equivalence.

Clinical evidence: generally not the default, but claims can change the evidentiary threshold

FDA’s position is explicit: clinical evidence is generally unnecessary for most dental composite resin devices. Yet the guidance also states that FDA may request clinical evidence where the sponsor makes performance statements about longevity, tooth remineralization, reduced decay, or other enhanced clinical outcomes. A sponsor may propose scientifically justified alternatives to clinical testing, but must be prepared to explain why the alternative adequately addresses the clinical question raised by the claim.

This creates an important strategic distinction between a conventional equivalence-based resin submission and a differentiated product narrative. The more the labeling, promotional material, instructions for use, or scientific dossier moves from describing a restorative material toward asserting superior or clinically enhanced outcomes, the more likely it is that bench, laboratory, and compositional evidence alone will be insufficient. Early alignment of claims, clinical strategy, predicate choice, and evidence-generation plan is therefore essential.

When evidence from a clinical investigation is needed, the guidance notes the potential relevance of the Investigational Device Exemptions regulation, including 21 CFR Part 812, as well as human-subject protections and institutional review board requirements for U.S. studies. FDA also identifies the Q-Submission program as a route for obtaining feedback on whether clinical data or a proposed clinical protocol is appropriate.

Dental curing lights: the new guidance treats the device as a complete technical system

The final curing-lights guidance is broader than a simple optical-output checklist. It covers device description, predicate comparison, labeling, reprocessing, biocompatibility, software, cybersecurity, electrical safety and electromagnetic compatibility (EMC), wireless technology, and non-clinical performance. The scope is appropriate for modern curing lights, which may combine LEDs, batteries, sensors, firmware, selectable modes, wireless interfaces, and reusable patient-contacting components.

The predicate comparison should address, among other points, indications for use, operational modes, light source, power source, accessories, maximum irradiance, radiant power output, peak wavelength, radiant exposure output range, and the composition of patient-contacting portions. A comparison that only identifies similar intended use and wavelength range is unlikely to be adequate where the subject device differs materially in energy delivery, software controls, battery architecture, reprocessing design, or connectivity.

Labeling and reprocessing

FDA recommends that instructions for use include total radiant power output, maximum irradiance, peak wavelength, radiant exposure range, recommended distance and angle from the tooth surface, relevant use of protective equipment, irradiance-check instructions, thermal-hazard warnings, and reuse information. Reprocessing instructions should address disassembly, cleaning, disinfection or sterilization, and reassembly where applicable.

The separate reprocessing section reflects the fact that many patient-contacting components of dental curing lights are reused. A robust submission should not treat cleaning instructions as an afterthought. It should document the reusable components, their material compatibility, the intended number and type of reprocessing cycles, the validation strategy, and the linkage between reprocessing and continued optical, mechanical, and biological safety.

Software, cybersecurity, and wireless functions

FDA generally considers device software functions in dental curing lights to require a Basic Documentation Level. New or unusual indications, applications, or technological characteristics may result in an Enhanced Documentation Level. The guidance also states that software changes must be revalidated and reverified, documented under ISO 13485:2016 design-and-development controls, and assessed for whether a new 510(k) may be warranted.

The cybersecurity discussion is important but should be framed accurately. FDA states that, if a curing light meets the statutory definition of a cyber device under section 524B(c) of the Federal Food, Drug, and Cosmetic Act, the cybersecurity documentation required by section 524B(b) must be included in the premarket submission. The guidance directs sponsors to FDA’s overarching cybersecurity guidance for the expected documentation.

Consequently, connectivity should trigger a deliberate statutory assessment, not an automatic conclusion. A Bluetooth, Wi-Fi, RFID, mobile-app, cloud, service-tool, or update pathway should be analyzed for its role in the device architecture, data flows, threat model, software supply chain, and risk-control framework. If the product is a statutory cyber device, the submission must satisfy the applicable legal cybersecurity requirements; if it is not, connectivity can still create safety, EMC, interoperability, or software-documentation questions that require a proportionate evidentiary response.

Optical output and heat: the performance evidence is more granular than a single irradiance value

The performance-testing section requires a multidimensional characterization of radiant output. FDA recommends evidence on total radiant power or flux throughout the exposure cycle; maximum irradiance at the distal end of the light guide; a spectral-irradiance plot showing peak wavelength and ultraviolet wavelengths; radiant exposure or optical radiation dose; irradiance attenuation from 0 to 10 mm; and a thermal image or beam profile identifying relative hot and cold spots across the light-guide tip.

This architecture makes scientific sense. A curing light can report a high nominal irradiance and still deliver an unsuitable energy profile due to spectral mismatch, non-uniform distribution, degradation across distance, operational-mode variation, or excessive local temperature. The submission should therefore explain not only the peak value, but also the relationship among spectrum, output, beam geometry, distance, exposure duration, resin compatibility, and user instructions.

The heat-generation section adds an explicit safety requirement: FDA recommends data demonstrating that temperatures remain safe for patient and practitioner under both normal and single-fault conditions. The sponsor should identify the maximum temperature at the device body and distal tip under the worst-case scenario, using the highest radiant exposure after a clinically relevant curing time.

The Federal Register notice records two meaningful refinements made after comments on the 2024 draft. For curing lights, FDA clarified that radiant power output should be measured at the tip, rather than 2 mm from the tip, and removed resin depth-of-cure measurements from the curing-lights guidance. Those details reinforce the need to consult the final text rather than rely on a draft or on legacy test matrices.

What the guidance changes operationally for manufacturers and 510(k) teams

The final guidances do not create a separate marketing pathway. Rather, they reshape how a sponsor should assemble and communicate its substantial-equivalence case. Their impact is likely to be most visible in the quality and traceability of the technical rationale: clearer formulation disclosure; cleaner alignment between claims and evidence; more complete systems engineering for curing lights; and more explicit lifecycle planning for shelf life, software, cybersecurity, and reprocessing.

The following readiness framework is a practical starting point for active and planned submissions.

A particularly useful approach is to establish a single evidence-to-claim traceability map. Each label claim and each predicate difference should be linked to the relevant test protocol, report, standard, device configuration, risk-control measure, and final submission section. This helps prevent a common failure mode: assembling strong individual reports that do not collectively answer the same regulatory question.

Can EU MDR technical documentation be reused?

Evidence generated for an EU Medical Device Regulation (MDR) technical file may be scientifically useful in a U.S. submission, but it is not interchangeable with a 510(k) submission by default. The final FDA dental guidances do not offer an automatic bridge or a blanket acceptance of MDR documentation. Instead, the manufacturer must show that every reused report is relevant to the U.S. device configuration, intended use, predicate comparison, test method, acceptance rationale, and FDA-recognized standards framework.

In practice, MDR evidence can often accelerate a U.S. program if it is well controlled, technically applicable, and accompanied by a transparent mapping analysis. Yet the U.S. dossier must retain its own FDA-specific structure and substantial-equivalence logic. A European comparison to a state-of-the-art benchmark does not replace a U.S. predicate comparison. Likewise, a clinical evaluation report does not automatically resolve the FDA question raised by a particular label claim. The correct framing is therefore: reuse where scientifically and regulatorily justified; do not assume regulatory portability.

Conclusions

The FDA’s 2 September 2026 final guidances are a substantive modernization of the 510(k) review framework for dental composite resin devices and dental curing lights. Their common theme is clearer linkage between device description, technological characteristics, risk, performance evidence, labeling, and predicate comparison. For composite resins, the pivotal shift is toward transparent, quantitative formulation control and a more integrated approach to elution, curing, shelf life, and biological evaluation. For curing lights, the shift is toward complete-system evidence that addresses optics, heat, electrical safety, software, wireless functions, cybersecurity, and reprocessing together.

The update should therefore be treated as a prompt for a focused portfolio review. Sponsors with active or planned 510(k) projects should compare their technical documentation and testing strategies against the final guidances, identify gaps early, and calibrate their regulatory and evidence plans to the specific configurations and claims they intend to bring to market. Where the device incorporates novel chemistry, differentiated clinical claims, connectivity, or non-standard operating modes, a targeted pre-submission discussion with FDA may be preferable to resolving foundational evidence questions late in review.

Image notice: The images in this article were generated using artificial intelligence. They do not depict real people, places, or events.